Income Statement
NEWAMSTERDAM PHARMA CO N.V.
NAMS
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
22.50 | 45.56 | 14.09 |
|
Cost of Revenue
|
- | - | - |
|
Gross Profit
|
22.50 | 45.56 | 14.09 |
|
Operating Expenses
|
248.19 | 221.85 | 197.06 |
|
Research & Development
|
141.83 | 151.41 | 159.42 |
|
Selling, General & Administrative
|
106.35 | 70.45 | 37.63 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-225.68 | -176.29 | -182.97 |
|
Non-Operating Income
|
-21.86 | 65.31 | -6.06 |
|
Interest Income
|
27.59 | 16.88 | 11.28 |
|
Interest Expense
|
- | - | - |
|
Other Non-Op Income / Expense
|
- | - | - |
|
Income Before Tax
|
-203.82 | -241.60 | -176.91 |
|
Income Tax Expense
|
0.00 | 0.00 | 0.03 |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-203.82 | -241.60 | -176.94 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-225.46 | -176.18 | -182.92 |
|
Earnings Per Share (Basic)
|
-1.72 | -2.56 | -2.15 |
|
Diluted EPS
|
-1.72 | -2.56 | -2.15 |
|
Weighted Average Shares
|
118.42 | 94.36 | 82.16 |
|
Diluted Weighted Avg Shares
|
118.42 | 94.36 | 82.16 |
|
Comprehensive Income
|
0.33 | 0.05 | -0.18 |